XBiotech Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XBIT research report →
Companywww.xbiotech.com
XBiotech Inc. , a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
- CEO
- Sushma Shivaswamy
- IPO
- 2015
- Employees
- 92
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $72.87M
- P/E
- -1.81
- P/S
- 0.00
- P/B
- 0.54
- EV/EBITDA
- 1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -26.10%
- ROIC
- -35.38%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-45,540,000 · -18.19%
- EPS
- $-1.49 · -18.25%
- Op Income
- $-55,685,000
- FCF YoY
- -24.61%
Performance & Tape
- 52W High
- $3.61
- 52W Low
- $2.09
- 50D MA
- $2.42
- 200D MA
- $2.55
- Beta
- 0.86
- Avg Volume
- 33.98K
Get TickerSpark's AI analysis on XBIT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 25 | Rademaker Craig Evan | other | 92,104 |
| Oct 1, 25 | Soffer David Spencer | other | 51,000 |
| Oct 1, 25 | Kuendig Thomas Martin | other | 79,115 |
| Oct 1, 25 | Troy Tevi David | other | 56,000 |
| Aug 29, 25 | Soffer David Spencer | other | 0 |
| Aug 29, 25 | Kuendig Thomas Martin | other | 0 |
| Aug 29, 25 | Kuendig Thomas Martin | other | 0 |
| Aug 29, 25 | Troy Tevi David | other | 0 |
| Aug 29, 25 | Rademaker Craig Evan | other | 0 |
| Aug 29, 25 | Rademaker Craig Evan | other | 0 |
Our XBIT Coverage
We haven't published any research on XBIT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XBIT Report →